Clin2
NCT07015164Possibly a fitNot yet recruiting

HIV virus hiding in the body while on treatment

HIV

Part of Infections clinical trials.

This study looks at why some people with HIV have very low but detectable virus in their blood despite taking their HIV medications. It may help doctors understand how the virus hides in the body.

Summary written for real people, not researchers, by Clin2.

Phase
N/A
Enrollment
80 people
Ages
18 years and older
Study type
Observational

Who can take part

  • You are 18 years or older and living with HIV.
  • You have been on HIV medications for at least 3 years.
  • You are on one of these specific medication combinations: Biktarvy, Triumeq, Descovy plus dolutegravir, Truvada plus dolutegravir, Truvada plus doravirine, or Epzicom plus doravirine.
  • If you have low but detectable virus (50–1,000 copies/mL) in at least 3 blood tests over the past year, you may be in a group with persistent viremia. If your virus has been undetectable (below 50 copies) for at least 2 years, there is a separate group for you.
  • No known resistance to your current HIV medications.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07745530Recruiting
How platelets affect HIV reservoirs in the blood

This study looks at how platelets (small blood cells that help with clotting) might influence the hidden HIV that remains in your body even when your viral load is undetectable. The goal is to understand why some people's immune systems don't fully recover despite effective HIV treatment.

Tourcoing
NCT05584397Enrolling by invitation
Compare immune activity and HIV hidden reservoir on two treatments

This study compares how active the immune system is and how large the “hidden” HIV reservoir is in people on two different HIV treatment types. It may help researchers understand whether staying on a tenofovir-containing regimen leads to better control of HIV hiding in the body.

Seattle, Washington
NCT06805656Recruiting· Phase 2
Trial to reduce HIV reservoirs aiming for treatment-free remission

This study tests whether a combination approach, including a drug called nicotinamide (a form of vitamin B3) and other strategies, can reduce the hidden HIV reservoir enough to allow a temporary pause in antiretroviral therapy without the virus rebounding. It is for people who have well-controlled HIV and strong immune systems.

São Paulo, São Paulo
NCT06016114Not yet recruiting
HIV reservoir study in people who control the virus

This study looks at the hidden HIV 'reservoir' in people who naturally control the virus or who have controlled it after stopping treatment. It aims to understand why some people's immune systems can keep HIV in check, which could lead to new treatments.

NCT00767312Enrolling by invitation
Study how HIV multiplies during HIV drug treatment

This study looks at how HIV continues to multiply (or stays suppressed) while you are taking antiretroviral therapy, using blood samples. It may help researchers better understand what HIV is doing during treatment and why some people experience changes like viral rebound.

Bethesda, Maryland
NCT02437526Enrolling by invitation
Testing an HIV treatment pause to see if cure is possible

This study looks at whether some people with HIV can keep the virus controlled even if they temporarily stop HIV medicines (an “analytic treatment interruption”). If you qualify, it may help researchers learn what it would take for an HIV cure.

Rochester, Minnesota

Hear when a new HIV trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.